Develop and manufacture instruments for life sciences research. Provide diagnostic solutions for early detection of genetic disorders. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
The gap is $2.6B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 42 buys and 37 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.28 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 7% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 57 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, RVTY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: RVTY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.